{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T15:52:14Z","timestamp":1782229934033,"version":"3.54.5"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100002386","name":"Cairo University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002386","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003009","name":"Science and Technology Development Fund","doi-asserted-by":"publisher","award":["28921"],"award-info":[{"award-number":["28921"]}],"id":[{"id":"10.13039\/501100003009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-05294-5","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T15:23:49Z","timestamp":1782228229000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Combination of p-STAT5, CRLF2 and copy number alterations as a potential indicator of a high-risk subgroup of acute lymphoblastic leukemia"],"prefix":"10.1007","volume":"17","author":[{"given":"Eman O.","family":"Rasekh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwa","family":"Hanafy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimaa","family":"Basha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdallah M.","family":"Almuslimani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youssef","family":"Madney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raafat","family":"Abd El-Fattah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azza M.","family":"Kamel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"5294_CR1","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/leu.2017.265","volume":"32","author":"N Toft","year":"2018","unstructured":"Toft N, Birgens H, Abrahamsson J, Gri\u0161kevi\u010dius L, Hallb\u00f6\u00f6k H, Heyman M, et al. Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia. Leukemia. 2018;32:606\u201315. https:\/\/doi.org\/10.1038\/leu.2017.265.","journal-title":"Leukemia"},{"key":"5294_CR2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1200\/JCO.2016.69.0073","volume":"35","author":"KG Roberts","year":"2017","unstructured":"Roberts KG, Gu Z, Payne-Turner D, McCastlain K, Harvey RC, Chen IM, et al. High frequency and poor outcome of Philadelphia Chromosome-Like acute lymphoblastic leukemia in adults. J Clin Oncol. 2017;35:394\u2013401. https:\/\/doi.org\/10.1200\/JCO.2016.69.0073.","journal-title":"J Clin Oncol"},{"key":"5294_CR3","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.semcancer.2020.10.013","volume":"84","author":"TH Tran","year":"2022","unstructured":"Tran TH, Hunger SP. The genomic landscape of pediatric acute lymphoblastic leukemia and precision medicine opportunities. Semin Cancer Biol. 2022;84:144\u201352. https:\/\/doi.org\/10.1016\/j.semcancer.2020.10.013.","journal-title":"Semin Cancer Biol"},{"key":"5294_CR4","unstructured":"- Hamdy N, Bhatia K, Shaker H, Kamel A, Nazli Gad-el-Mawla, Abou-Enein M, et al. Molecular epidemiology of acute lymphoblastic leukemia in Egypt. Leukemia 1995;9(1):194\u2013202."},{"key":"5294_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106210","volume":"80","author":"P Xin","year":"2020","unstructured":"Xin P, Xu X, Deng C, Liu S, Wang Y, Zhou X, et al. The role of JAK\/STAT signaling pathway and its inhibitors in diseases. Int Immunopharmacol. 2020;80:106210. https:\/\/doi.org\/10.1016\/j.intimp.2020.106210.","journal-title":"Int Immunopharmacol"},{"issue":"8","key":"5294_CR6","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1038\/s41375-018-0117-x","volume":"32","author":"B Wingelhofer","year":"2018","unstructured":"Wingelhofer B, Neubauer HA, Valent P, Han X, Constantinescu SN, Gunning PT, et al. Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer. Leukemia. 2018;32(8):1713\u201326. https:\/\/doi.org\/10.1038\/s41375-018-0117-x.","journal-title":"Leukemia"},{"key":"5294_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25136844","volume":"25","author":"KJ Zi\u0119tara","year":"2024","unstructured":"Zi\u0119tara KJ, Wr\u00f3blewska K, Zaj\u0105czkowska M, Tacza\u0142a J, Lejman M. The role of the JAK\u2013STAT pathway in childhood B-Cell acute lymphoblastic leukemia. Int J Mol Sci. 2024;25:6844.","journal-title":"Int J Mol Sci"},{"key":"5294_CR8","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1038\/s41375-018-0369-5","volume":"33","author":"S Kollmann","year":"2019","unstructured":"Kollmann S, Grundschober E, Maurer B, Warsch W, Grausenburger R, Edlinger L, et al. Twins with different personalities: STAT5B\u2014but not STAT5A\u2014has a key role in BCR\/ABL-induced leukemia. Leukemia. 2019;33:1583\u201397. https:\/\/doi.org\/10.1038\/s41375-018-0369-5.","journal-title":"Leukemia"},{"key":"5294_CR9","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ebiom.2016.04.038","volume":"8","author":"YF Liu","year":"2016","unstructured":"Liu YF, Wang BY, Zhang WN, Huang JY, Li BS, Zhang M, et al. Genomic profiling of adult and pediatric B-cell acute lymphoblastic leukemia. EBioMedicine. 2016;8:173\u201383. https:\/\/doi.org\/10.1016\/j.ebiom.2016.04.038.","journal-title":"EBioMedicine"},{"issue":"1","key":"5294_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-020-00998-5","volume":"23","author":"B Rosales-Rodr\u00edguez","year":"2021","unstructured":"Rosales-Rodr\u00edguez B, N\u00fa\u00f1ez-Enr\u00edquez JC, Mej\u00eda-Arangur\u00e9 JM, Rosas-Vargas H. Prognostic impact of somatic copy number alterations in childhood B-Lineage acute lymphoblastic leukemia. Curr Oncol Rep. 2021;23(1):2. https:\/\/doi.org\/10.1007\/s11912-020-00998-5.","journal-title":"Curr Oncol Rep"},{"key":"5294_CR11","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.celrep.2013.10.038","volume":"5","author":"M Waibel","year":"2013","unstructured":"Waibel M, Solomon VS, Knight DA, Ralli RA, Kim SK, Banks KM, et al. Combined targeting of JAK2 and Bcl-2\/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors. Cell Rep. 2013;5:1047\u201359. https:\/\/doi.org\/10.1016\/j.celrep.2013.10.038.","journal-title":"Cell Rep"},{"key":"5294_CR12","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1200\/JCO.2016.70.7836","volume":"35","author":"I Iacobucci","year":"2017","unstructured":"Iacobucci I, Mullighan CG. Genetic basis of acute lymphoblastic leukemia. J Clin Oncol. 2017;35:975\u201383. https:\/\/doi.org\/10.1200\/JCO.2016.70.7836.","journal-title":"J Clin Oncol"},{"key":"5294_CR13","doi-asserted-by":"publisher","unstructured":"- Kamel AM, Almuslimani AM, Kandil EZ, Hanafy M, Samra MAM, Madeny YMS, Osman RA. PD1\/PDL1 and TIM3\/Gal9 expression in acute lymphoblastic leukemia: Gal-9 expression on leukemia stem cells as an independent prognostic parameter. BMC 2025 Online. https:\/\/doi.org\/10.1186\/s12885-025-14856-9","DOI":"10.1186\/s12885-025-14856-9"},{"key":"5294_CR14","doi-asserted-by":"publisher","DOI":"10.3791\/52241","volume":"18","author":"V Menon","year":"2014","unstructured":"Menon V, Thomas R, Ghale AR, Reinhard C, Pruszak J. Flow cytometry protocols for surface and intracellular antigen analyses of neural cell types. J Vis Exp. 2014;18:52241. https:\/\/doi.org\/10.3791\/52241.","journal-title":"J Vis Exp"},{"key":"5294_CR15","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/cyto.b.21518","volume":"94B","author":"MN Dworzak","year":"2018","unstructured":"Dworzak MN, Buldini B, Gaipa G, Ratei R, Hrusak O, Luria D, et al. AIEOP-BFM consensus guidelines 2016 for flow cytometric immunophenotyping of pediatric acute lymphoblastic leukemia. Cytometry B Clin Cytom. 2018;94B:82\u201393.","journal-title":"Cytometry B Clin Cytom"},{"key":"5294_CR16","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1056\/NEJMra052603","volume":"354","author":"CH Pui","year":"2006","unstructured":"Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354:166\u201378. https:\/\/doi.org\/10.1056\/NEJMra052603.","journal-title":"N Engl J Med"},{"key":"5294_CR17","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/S0140-6736(07)61126-X","volume":"370","author":"R Pieters","year":"2007","unstructured":"Pieters R, Schrappe M, De Lorenzo P, Hann I, De Rossi G, Felice M, et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet. 2007;370:240\u201350. https:\/\/doi.org\/10.1016\/S0140-6736(07)61126-X.","journal-title":"Lancet"},{"key":"5294_CR18","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1016\/s0889-8588(05)70188-x","volume":"14","author":"N G\u00f6kbuget","year":"2000","unstructured":"G\u00f6kbuget N, Hoelzer D, Arnold R, B\u00f6hme A, Bartram CR, Freund M, et al. Treatment of adult ALL according to protocols of the German Multicenter Study Group for adult ALL (GMALL). Hematol Oncol Clin North Am. 2000;14:1307\u201325. https:\/\/doi.org\/10.1016\/s0889-8588(05)70188-x.","journal-title":"Hematol Oncol Clin North Am"},{"key":"5294_CR19","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1182\/blood-2006-06-027714","volume":"109","author":"A Moghrabi","year":"2007","unstructured":"Moghrabi A, Levy DE, Asselin B, Barr R, Clavell L, Hurwitz C, et al. Results of the Dana-Farber Cancer Institute ALL consortium protocol 95\u201301 for children with acute lymphoblastic leukemia. Blood. 2007;109:896\u2013904. https:\/\/doi.org\/10.1182\/blood-2006-06-027714.","journal-title":"Blood"},{"key":"5294_CR20","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1111\/bjh.19467","volume":"205","author":"X Xu","year":"2024","unstructured":"Xu X, Huang Z, Ding C, Deng S, Ou J, Cai Z, et al. STAT5 phosphorylation plus minimal residual disease defines a novel risk classification in adult b-cell acute lymphoblastic leukaemia. Br J Haematol. 2024;205:517\u201328. https:\/\/doi.org\/10.1111\/bjh.19467.","journal-title":"Br J Haematol"},{"issue":"1","key":"5294_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101291","volume":"15","author":"ALT Maciel","year":"2022","unstructured":"Maciel ALT, Barbosa T, Barbieri Blunck C, Wolch K, Machado AD, da Costaet ES. IKZF1 deletions associate with CRLF2 overexpression leading to a poor prognosis in B-cell precursor acute lymphoblastic leukaemia. Transl Oncol. 2022;15(1):101291. https:\/\/doi.org\/10.1016\/j.tranon.2021.101291.","journal-title":"Transl Oncol"},{"key":"5294_CR22","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.1182\/blood-2021-153309","volume":"138","author":"EA Huante","year":"2021","unstructured":"Huante EA, Rangel-Pati\u00f1o J, C\u00f3rdova-Serrano RD, Espinosa KA, Demichelis R. Over-expression of CRLF2 by flow cytometry (FC) impacts on overall survival (OS) in Mexican patients with acute lymphoblastic leukemia (ALL). Blood. 2021;138:3367. https:\/\/doi.org\/10.1182\/blood-2021-153309.","journal-title":"Blood"},{"key":"5294_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1256054","volume":"13","author":"D Lin","year":"2023","unstructured":"Lin D, Yang K, Yu L, Huang L, Lai X, Wu L, et al. Poor outcome of pediatric b-cell acute lymphoblastic leukemia associated with high level of CRLF2 gene expression in distinct molecular subtypes. Front Oncol. 2023;13:1256054. https:\/\/doi.org\/10.3389\/fonc.2023.1256054.","journal-title":"Front Oncol"},{"key":"5294_CR24","doi-asserted-by":"publisher","unstructured":"- Noronha EP, Ferreira PMS, Andrade FG, Blunck CB, Camargo, R, Gimba, et al. Multiparametric flow cytometry directing the evaluation of CRLF2 rearrangements and JAK2 status in pediatric B cell precursor acute lymphoblastic leukemia. Hematol Transfus Cell Ther 2023;45:245\u201352. https:\/\/doi.org\/10.1016\/j.htct.2022.06.008.","DOI":"10.1016\/j.htct.2022.06.008"},{"issue":"52","key":"5294_CR25","doi-asserted-by":"publisher","first-page":"89923","DOI":"10.18632\/oncotarget.21027","volume":"8","author":"EMP Steeghs","year":"2017","unstructured":"Steeghs EMP, Jerchel IS, de Goffau-Nobel W, Hoogkamer AQ, Boer JM, Boeree A, et al. JAK2 aberrations in childhood b-cell precursor acute lymphoblastic leukemia. Oncotarget. 2017;8(52):89923\u201338. https:\/\/doi.org\/10.18632\/oncotarget.21027.","journal-title":"Oncotarget"},{"issue":"21","key":"5294_CR26","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1182\/blood.V120.21.2518.2518","volume":"120","author":"N Hasan","year":"2012","unstructured":"Hasan N, Bresolin S, Bronzini I, Palmi C, Queudeville M, Eckhoff SM, et al. CRLF2 rearrangement is not associated with activated mTOR pathway in NOD\/SCID\/huALL xenograft mouse model. Blood. 2012;120(21):2518. https:\/\/doi.org\/10.1182\/blood.V120.21.2518.2518.","journal-title":"Blood"},{"key":"5294_CR27","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.leukres.2015.11.018","volume":"41","author":"S Chiaretti","year":"2016","unstructured":"Chiaretti S, Brugnoletti F, Messina M, Paoloni F, Fedullo AL, Piciocchi A, et al. CRLF2 overexpression identifies an unfavourable subgroup of adult B-cell precursor acute lymphoblastic leukemia lacking recurrent genetic abnormalities. Leuk Res. 2016;41:36\u201342. https:\/\/doi.org\/10.1016\/j.leukres.2015.11.018.","journal-title":"Leuk Res"},{"key":"5294_CR28","doi-asserted-by":"publisher","first-page":"49722","DOI":"10.18632\/oncotarget.10437","volume":"7","author":"Z Ge","year":"2016","unstructured":"Ge Z, Gu Y, Zhao G, Li J, Chen B, Han Q, et al. High CRLF2 expression associates with IKZF1 dysfunction in adult acute lymphoblastic leukemia without CRLF2 rearrangement. Oncotarget. 2016;7:49722\u201332.","journal-title":"Oncotarget"},{"issue":"1","key":"5294_CR29","first-page":"17","volume":"9","author":"A Kamel","year":"2013","unstructured":"Kamel A, El-Sharkawy N, Meshaal S, Labib D, Kamel MM, Samra M, et al. Expression of phosphorylated STAT5 in chronic myeloid leukemia: relation to disease stages. J Egypt Soc Hematol Res. 2013;9(1):17\u201323.","journal-title":"J Egypt Soc Hematol Res"},{"key":"5294_CR30","doi-asserted-by":"publisher","first-page":"3512","DOI":"10.1182\/blood-2011-11-394221","volume":"119","author":"IM Chen","year":"2012","unstructured":"Chen IM, Harvey RC, Mullighan CG, Gastier-Foster J, Wharton W, Kang H, et al. Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children\u2019s Oncology Group study. Blood. 2012;119:3512\u201322. https:\/\/doi.org\/10.1182\/blood-2011-11-394221.","journal-title":"Blood"},{"key":"5294_CR31","doi-asserted-by":"publisher","first-page":"25971","DOI":"10.18632\/oncotarget.25411","volume":"9","author":"A Pastorczak","year":"2018","unstructured":"Pastorczak A, Sedek L, Braun M, Madzio J, Sonsala A, Twardoch M, et al. Surface expression of cytokine receptor-like factor 2 increases risk of relapse in pediatric acute lymphoblastic leukemia patients harboring IKZF1 deletions. Oncotarget. 2018;9:25971\u201382. https:\/\/doi.org\/10.18632\/oncotarget.25411.","journal-title":"Oncotarget"},{"issue":"13","key":"5294_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13133289","volume":"13","author":"M Ampatzidou","year":"2021","unstructured":"Ampatzidou M, Florentin L, Papadakis V, Paterakis G, Tzanoudaki M, Bouzarelou D, et al. Copy number alteration profile provides additional prognostic value for acute lymphoblastic leukemia patients treated on BFM protocols. Cancers (Basel). 2021;13(13):3289. https:\/\/doi.org\/10.3390\/cancers13133289.","journal-title":"Cancers (Basel)"},{"key":"5294_CR33","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/s41375-021-01448-2","volume":"36","author":"AV Moorman","year":"2022","unstructured":"Moorman AV, Barretta E, Butler ER, Ward EJ, Twentyman K, Kirkwood AA, et al. Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 study. Leukemia. 2022;36:625\u201336. https:\/\/doi.org\/10.1038\/s41375-021-01448-2.","journal-title":"Leukemia"},{"issue":"4","key":"5294_CR34","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.phoj.2021.11.006","volume":"6","author":"M Agarwal","year":"2021","unstructured":"Agarwal M, Shukla R, Dwivedi SN, Saxena R, Luthra K, Kabra M, et al. Gene copy number alterations in Indian children with B-acute lymphoblastic leukemia: correlation with survival outcome. Pediatr Hematol Oncol J. 2021;6(4):151\u20137. https:\/\/doi.org\/10.1016\/j.phoj.2021.11.006.","journal-title":"Pediatr Hematol Oncol J"},{"key":"5294_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12828-z","volume":"24","author":"L Pan","year":"2024","unstructured":"Pan L, Chen Y, Weng K, Guo B, Zhuang S, Huang S, et al. Prognostic significance and treatment strategies for IKZF1 deletion in pediatric B-cell precursor acute lymphoblastic leukemia. BMC Cancer. 2024;24:1070. https:\/\/doi.org\/10.1186\/s12885-024-12828-z.","journal-title":"BMC Cancer"},{"key":"5294_CR36","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1182\/blood.2019000813","volume":"135","author":"M Stanulla","year":"2020","unstructured":"Stanulla M, Cav\u00e9 H, Moorman AV. IKZF1 deletions in pediatric acute lymphoblastic leukemia: still a poor prognostic marker? Blood. 2020;135:252\u201360. https:\/\/doi.org\/10.1182\/blood.2019000813.","journal-title":"Blood"},{"key":"5294_CR37","doi-asserted-by":"publisher","unstructured":"Stanulla M, Dagdan E., Zaliova M, M\u00f6ricke A, Palmi C, Cazzaniga G, et al. International BFM Study Group. IKZF1plus defines a new minimal residual disease-dependent very-poor prognostic profile in pediatric B-cell precursor acute lymphoblastic leukemia. J Clin Oncol 2018;36:1240-9. https:\/\/doi.org\/10.1200\/JCO.2017.74.3617","DOI":"10.1200\/JCO.2017.74.3617"},{"issue":"6","key":"5294_CR38","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1084\/jem.20101947","volume":"208","author":"LM Heltemes-Harris","year":"2011","unstructured":"Heltemes-Harris LM, Willette MJ, Ramsey LB, Qiu YH, Neeley ES, Zhang N, et al. Ebf1 or Pax5 haploinsufficiency synergizes with STAT5 activation to initiate acute lymphoblastic leukemia. J Exp Med. 2011;208(6):1135\u201349. https:\/\/doi.org\/10.1084\/jem.20101947.","journal-title":"J Exp Med"},{"key":"5294_CR39","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V122.21.1313.1313","volume":"122","author":"RP Kuiper","year":"2013","unstructured":"Kuiper RP, Scheijen B, Pastorczak A, Reijmersdal SV, Thomas DA, Zhang N, et al. Identification of distinct protein signatures associated with genetic abnormalities in acute lymphoblastic leukemia. Blood. 2013;122:1313. https:\/\/doi.org\/10.1182\/blood.V122.21.1313.1313.","journal-title":"Blood"},{"key":"5294_CR40","doi-asserted-by":"publisher","first-page":"5793","DOI":"10.1158\/0008-5472.CAN-18-0195","volume":"78","author":"V Minieri","year":"2018","unstructured":"Minieri V, De Dominici M, Porazzi P, Mariani SA, Spinelli O, Rambaldi A, et al. Targeting STAT5 or STAT5-regulated pathways suppresses leukemogenesis of Ph+ acute lymphoblastic leukemia. Cancer Res. 2018;78:5793\u2013807. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-0195.","journal-title":"Cancer Res"},{"key":"5294_CR41","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1182\/bloodadvances.2023012162","volume":"8","author":"I Van Outersterp","year":"2024","unstructured":"Van Outersterp I, Boer JM, van de Ven C, Reichert CEJ, Boeree A, Kruisinga B, et al. Tyrosine kinase inhibitor resistance in de novo BCR::ABL1-positive BCP-ALL beyond kinase domain mutations. Blood Adv. 2024;8:1835\u201345. https:\/\/doi.org\/10.1182\/bloodadvances.2023012162.","journal-title":"Blood Adv"},{"key":"5294_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2022.155896","volume":"155","author":"MdR Ju\u00e1rez-Vel\u00e1zquez","year":"2022","unstructured":"Ju\u00e1rez-Vel\u00e1zquez MdR, Moreno-Lorenzana DL, Anaya DAM, Monterd EAH, Aguilar-Hern\u00e1ndez MM, et al. High occurrence of CRLF2 abnormalities in Mexican children with B-cell acute lymphoblastic leukemia. Cytokine. 2022;155:1043-4666. https:\/\/doi.org\/10.1016\/j.cyto.2022.155896.","journal-title":"Cytokine"},{"key":"5294_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-015-0017-y","author":"NE Van der Sligte","year":"2015","unstructured":"Van der Sligte NE, Scherpen FJ, Ter Elst A, Guryev V, van Leeuwen FN, de Bont ES. Effect of IKZF1 deletions on signal transduction pathways in Philadelphia chromosome negative pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Exp Hematol Oncol. 2015. https:\/\/doi.org\/10.1186\/s40164-015-0017-y.","journal-title":"Exp Hematol Oncol"},{"issue":"3","key":"5294_CR44","doi-asserted-by":"publisher","first-page":"121","DOI":"10.21608\/jcbr.2021.59346.1126","volume":"5","author":"A Shibl","year":"2021","unstructured":"Shibl A, Sayed HA, Ali AM, Mohamed DO, Abdelhamid ON. Long term survival outcome of childhood acute lymphoblastic leukemia treated with modified TXIIIB protocol at South Egypt Cancer Institute. Int J Cancer Biomed Res. 2021;5(3):121\u201332. https:\/\/doi.org\/10.21608\/jcbr.2021.59346.1126.","journal-title":"Int J Cancer Biomed Res"},{"issue":"4","key":"5294_CR45","first-page":"2","volume":"5","author":"B Chen","year":"2022","unstructured":"Chen B, Shi Z. Clinical and prognostic analysis of adult acute lymphoblastic leukemia. Clin Oncol Res. 2022;5(4):2\u20138.","journal-title":"Clin Oncol Res"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-05294-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05294-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05294-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T15:44:58Z","timestamp":1782229498000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-05294-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5294"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-05294-5","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"12 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutional Review Board (IRB) of the National Cancer Institute, Cairo University, [approval number: 202101-03-02001]. The study was conducted in accordance with the ethical principles of the Declaration of Helsinki, with full respect for human rights, dignity, confidentiality, and participant welfare. A written informed consent was obtained from all participants or their legal guardians.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"935"}}